Treats advanced metastatic colorectal cancer. ANDA 210892, held by Gland. Levoleucovorin Calcium.
As of Nov 16, 2026, ANDA 210892 (Levoleucovorin Calcium), held by Gland, was first approved by FDA on Sep 14, 2018, with 2 approved supplements and 0 published complete response letters.
Levoleucovorin injection is a folate analog. Levoleucovorin injection rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. Levoleucovorin injection is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. Levoleucovor injection is a folate analog indicated for: · Rescue after high-dose methotrexate therapy in osteosarcoma.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 14, 2018 | Original application | Approved |
| Levoleucovorin CalciumEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) · solution;intravenous | Levoleucovorin Calcium | Rx |
| Levoleucovorin CalciumEQ 250MG BASE/25ML (EQ 10MG BASE/ML) · solution;intravenous | Levoleucovorin Calcium | Rx |
| Jul 12, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 12, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 14, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters